Andere Sprachen Arvinas, Inc.

Aktien

A2N6VP

US04335A1051

ARVN

Markt geschlossen - Nasdaq Andere Börsenplätze 22:00:00 24.04.2024			% 5 Tage	% 1. Jan.
32.54 ^USD	-4.29%		-2.72%	-20.94%

15.04.	ARVINAS, INC. : HC Wainwright behält die Bewertung Kaufen bei	ZM
12.04.	ARVINAS, INC. : HC Wainwright bleibt bei seiner Kaufempfehlung	ZM

Andere Sprachen

Erhalten Sie Zugang zu allen Nachrichten über alle Unternehmen: Verpassen Sie keine profitable Anlagechance mehr!

100% kostenlose Registrierung

Arvinas Appoints Randy Teel, Ph.D., as Chief Business Officer	24.04.
Arvinas : 2024 Proxy Statement	17.04.
Arvinas enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC Androgen Receptor Protein Degrader ARV-766 for the Treatment of Prostate Cancer	12.04.
Novartis Secures Exclusive Licensing Deal with Arvinas for Prostate Cancer Drug	12.04.
Fastenal, CarMax fall; Alpine Immune Sciences, Arvinas rise, Thursday, 4/11/2024	11.04.
Novartis : accord de licence dans le cancer de la prostate	11.04.
Arvinas Agrees to License Prostate Cancer Treatment, Sell AR-V7 Program to Novartis	11.04.
Novartis étend sa recherche contre le cancer de la prostate	11.04.
Arvinas, Novartis in ARV-766 Prostate Cancer License Pact	11.04.
Novartis licenses Arvinas' cancer drug for up to $1 billion	11.04.
Arvinas Enters into a Transaction with Novartis, including a Global License Agreement for the Development and Commercialization of PROTAC® Androgen Receptor (AR) Protein Degrader ARV-766 for the Treatment of Prostate Cancer	11.04.
Arvinas, Inc Enters into an Exclusive Strategic License Agreement with Novartis AG for the Development and Commercialization of Protac Androgen Receptor Protein Degrader Arv-766 for the Treatment of Prostate Cancer	11.04.
Arvinas Appoints Noah Berkowitz as Chief Medical Officer	18.03.
Arvinas Appoints Noah Berkowitz, M.D., Ph.D., as Chief Medical Officer	18.03.
Arvinas, Inc. Appoints Noah Berkowitz as Chief Medical Officer and A Member of the Executive Committee	18.03.
Arvinas to Participate in Upcoming Investor Conferences	04.03.
Arvinas' Q4 Net Loss Widens as Company Reports No Revenue	27.02.
Arvinas, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	27.02.
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	27.02.
Arvinas Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update	27.02.

Keine Ergebnisse zu dieser Suche

Alle Nachrichten Analystenempfehlungen Wichtige Fakten Insiders Transkripte Pressemitteilungen Offizielle Publikationen Andere Sprachen Trading-Ideen MarketScreener Artikel MarketScreener Analysen

Andere Sprachen Arvinas, Inc.

Aktien

A2N6VP

US04335A1051

ARVN

Andere Sprachen

Filter